PMID- 20550459
OWN - NLM
STAT- MEDLINE
DCOM- 20110208
LR  - 20131121
IS  - 1556-9535 (Electronic)
IS  - 1556-9527 (Linking)
VI  - 29
IP  - 4
DP  - 2010 Dec
TI  - Fentanyl transdermal patches: overview of cutaneous adverse effects in humans.
PG  - 241-6
LID - 10.3109/15569527.2010.492487 [doi]
AB  - Using Medline, Embase, and the Science Citation Index, we summarize the cutaneous 
      adverse effects of transdermal and parenteral fentanyl. The fentanyl transdermal 
      therapeutic system (TTS; patch) provides continuous systemic delivery of fentanyl 
      (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl) propanamide), a potent opioid 
      analgesic, for 72 hours. Clinical studies of fentanyl TTSs demonstrated varying 
      rates of irritation at the application site, ranging from none to 42%, with a 
      median of 25%. Most descriptions of skin reactions included erythema at the 
      application site, indicating irritant dermatitis. Skin testing in 2 subjects 
      receiving parenteral doses concluded that although immunoglobulin E (IgE) 
      antibodies to fentanyl exist, few cases of immediate-type allergic reactions to 
      fentanyl have been substantiated. Comparing the reactions to anesthetic agents 
      during allergenic testing demonstrated positive "wheal and flare" to fentanyl in 
      only 1 of 50 patients (2%). Pruritus has been frequently reported during 
      administration of epidural fentanyl, but allergenicity has not been shown. The 
      few case reports of possible anaphylactic reactions to fentanyl have not clearly 
      demonstrated fentanyl as the causal agent. In addition, transdermal and 
      intravenous/epidural routes of administration may not be comparable because of 
      large differences in plasma concentrations: When these results are taken 
      together, fentanyl (TTS) has shown limited skin intolerance.
FAU - Hostynek, Jurij J
AU  - Hostynek JJ
AD  - Department of Dermatology, UCSF School of Medicine, University of California San 
      Francisco, California 94143-0989, USA. jurij.hostynek65@gmail.com
FAU - Maibach, Howard I
AU  - Maibach HI
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100616
PL  - England
TA  - Cutan Ocul Toxicol
JT  - Cutaneous and ocular toxicology
JID - 101266892
RN  - 0 (Analgesics, Opioid)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Analgesics, Opioid/*adverse effects
MH  - Dermatitis, Allergic Contact/*etiology/pathology
MH  - Dermatitis, Irritant/*etiology/pathology
MH  - Erythema/*chemically induced/pathology
MH  - Female
MH  - Fentanyl/*adverse effects
MH  - Humans
MH  - Male
MH  - Quantitative Structure-Activity Relationship
MH  - Skin/*drug effects/pathology
MH  - Skin Tests
MH  - Transdermal Patch
EDAT- 2010/06/17 06:00
MHDA- 2011/02/09 06:00
CRDT- 2010/06/17 06:00
PHST- 2010/06/17 06:00 [entrez]
PHST- 2010/06/17 06:00 [pubmed]
PHST- 2011/02/09 06:00 [medline]
AID - 10.3109/15569527.2010.492487 [doi]
PST - ppublish
SO  - Cutan Ocul Toxicol. 2010 Dec;29(4):241-6. doi: 10.3109/15569527.2010.492487. Epub 
      2010 Jun 16.